{"title_page": "Revaprazan", "text_new": "{{Infobox drug\n| drug_name = \n| IUPAC_name        =  ''N''-(4-Fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1''H'')-isoquinolinyl)-2-pyrimidinamine\n| image             = Revaprazan.svg\n| alt               = \n| caption           =\n\n<!-- Clinical data -->\n| tradename         = Revanex<ref>{{cite web | url = https://www.drugs.com/international/revaprazan.html | title = Revaprazan | publisher = drugs.com}}</ref>\n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      = <!-- A / B            / C / D / X -->\n| pregnancy_category= \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration =\n\n<!-- Pharmacokinetic data -->\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         =\n\n<!-- Identifiers -->\n| CAS_number        = 199463-33-7\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 5P184180P5\n| ATCvet            = \n| ATC_prefix        = None\n| ATC_suffix        = \n| PubChem = 204104\n| ChemSpiderID = 176801\n| DrugBank          = \n| synonyms = YH1885\n\n<!-- Chemical data -->\n| C=22 | H=23 | F=1 | N=4\n| molecular_weight  = 362.44 g/mol\n| smiles = c1cc(F)ccc1Nc2nc(C)c(C)c(n2)N3CCc4ccccc4C3C\n| StdInChI = 1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26)\n| StdInChIKey = LECZXZOBEZITCL-UHFFFAOYSA-N\n}}\n\n'''Revaprazan''' (trade name '''Revanex''') is a drug that reduces [[gastric acid]] secretion which is used for the treatment of [[gastritis]].<ref>{{cite journal | journal = J Gastroenterol Hepatol | date = Oct 2010 | volume = 25 | issue = 10 | pages = 1618\u20131625 | doi= 10.1111/j.1440-1746.2010.06408.x | title = Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects |vauthors=Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS | pmid= 20880169}}</ref> It acts as an acid pump antagonist<ref>{{cite journal | title = Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers |vauthors=Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS | journal = J Clin Pharmacol | date = Jan 2004 | volume = 44 | issue = 1 | pages = 73\u201382 | pmid=14681344 | doi=10.1177/0091270003261321}}</ref> ([[potassium-competitive acid blocker]]). Revaprazan is approved for use in South Korea,<ref>{{Cite web | url = http://business.highbeam.com/436989/article-1G1-151758768/revaprazan-yuhan-registered-south-korea | archive-url = https://web.archive.org/web/20140429190723/http://business.highbeam.com/436989/article-1G1-151758768/revaprazan-yuhan-registered-south-korea | url-status = dead | archive-date = April 29, 2014 | title = Revaprazan Yuhan registered, South Korea (gastritis) | publisher = R & D Focus Drug News | date = September 25, 2006}}</ref> but is not approved in Europe or the United States.\n\n==References==\n{{reflist}}\n\n{{Proton-Pump Inhibitors}}\n\n[[Category:Proton pump inhibitors]]\n[[Category:Anilines]]\n[[Category:Organofluorides]]\n[[Category:Aminopyrimidines]]\n[[Category:Tetrahydroisoquinolines]]\n\n\n{{Gastrointestinal-drug-stub}}\n", "text_old": "{{Infobox drug\n| drug_name = \n| IUPAC_name        =  ''N''-(4-Fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1''H'')-isoquinolinyl)-2-pyrimidinamine\n| image             = Revaprazan.svg\n| alt               = \n| caption           =\n\n<!-- Clinical data -->\n| tradename         = Revanex<ref>{{cite web | url = https://www.drugs.com/international/revaprazan.html | title = Revaprazan | publisher = drugs.com}}</ref>\n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      = <!-- A / B            / C / D / X -->\n| pregnancy_category= \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration =\n\n<!-- Pharmacokinetic data -->\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         =\n\n<!-- Identifiers -->\n| CAS_number        = 199463-33-7\n| ATCvet            = \n| ATC_prefix        = None\n| ATC_suffix        = \n| PubChem = 204104\n| ChemSpiderID = 176801\n| DrugBank          = \n| synonyms = YH1885\n\n<!-- Chemical data -->\n| C=22 | H=23 | F=1 | N=4\n| molecular_weight  = 362.44 g/mol\n| smiles = c1cc(F)ccc1Nc2nc(C)c(C)c(n2)N3CCc4ccccc4C3C\n| StdInChI = 1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26)\n| StdInChIKey = LECZXZOBEZITCL-UHFFFAOYSA-N\n}}\n\n'''Revaprazan''' (trade name '''Revanex''') is a drug that reduces [[gastric acid]] secretion which is used for the treatment of [[gastritis]].<ref>{{cite journal | journal = J Gastroenterol Hepatol | date = Oct 2010 | volume = 25 | issue = 10 | pages = 1618\u20131625 | doi= 10.1111/j.1440-1746.2010.06408.x | title = Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects |vauthors=Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS | pmid= 20880169}}</ref> It acts as an acid pump antagonist<ref>{{cite journal | title = Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers |vauthors=Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS | journal = J Clin Pharmacol | date = Jan 2004 | volume = 44 | issue = 1 | pages = 73\u201382 | pmid=14681344 | doi=10.1177/0091270003261321}}</ref> ([[potassium-competitive acid blocker]]). Revaprazan is approved for use in South Korea,<ref>{{Cite web | url = http://business.highbeam.com/436989/article-1G1-151758768/revaprazan-yuhan-registered-south-korea | archive-url = https://web.archive.org/web/20140429190723/http://business.highbeam.com/436989/article-1G1-151758768/revaprazan-yuhan-registered-south-korea | url-status = dead | archive-date = April 29, 2014 | title = Revaprazan Yuhan registered, South Korea (gastritis) | publisher = R & D Focus Drug News | date = September 25, 2006}}</ref> but is not approved in Europe or the United States.\n\n==References==\n{{reflist}}\n\n{{Proton-Pump Inhibitors}}\n\n[[Category:Proton pump inhibitors]]\n[[Category:Anilines]]\n[[Category:Organofluorides]]\n[[Category:Aminopyrimidines]]\n[[Category:Tetrahydroisoquinolines]]\n\n\n{{Gastrointestinal-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Revaprazan"}
